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Abstract
Background: Prostate-specific antigen (PSA) screening more frequently detects early stage prostate cancer (PC).
However, adverse pathologic features (APFs) after radical prostatectomy (RP) in low-risk PC occur. Previous related
studies had utilized outdated staging criteria or small sample cohorts. In this study, we analyzed predictors of APFs
after RP in low-risk PC using classification under the current criteria.
Materials and methods: We retrospectively reviewed medical records of 546 low-risk PC patients who had
undergone RP. Low-risk PC was defined as PC with clinical T1–T2a, Gleason score ≤ 6, and PSA levels < 10 ng/mL.
Clinical and pathological parameters were analyzed to predict APFs. APFs were defined as extracapsular extension
(ECE), seminal vesicle invasion (SVI), or positive surgical margins (PSM). We analyzed our data using univariable and
multivariable logistic regression analyses, as well as receiver operator characteristics to predict APFs.
Results: Among 546 patients, ECE, SVI, and PSM were present in 199 (36.4%), 8 (1.5%), and 179 cases (32.8%), respectively.
PSM had a significant correlation with preoperative high PSA levels and number of positive cores obtained. ECE/SVI was
also significantly correlated with PSA levels and number of positive cores. As a result, presence of APFs after RP was
associated with high PSA levels and large number of positive cores. PSA > 4.5 ng/mL and number of positive cores > 2 in
low-risk PC were significantly associated with APFs, and suggested as cut-off values for predicting APFs.
Conclusions: PSA > 4.5 ng/mL and number of positive cores > 2 in low-risk PC were associated with presence of APFs
and patients with such records should be considered carefully to provide active surveillance.
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Background
Prostate cancer (PC) is the most common type of newly
diagnosed malignancy in males [1] and it accounts for
nearly 30% of all diagnosed male cancers [2]. As PC
screening by measuring prostate-specific antigen (PSA)
levels has become more widespread, the proportion of
PC presenting with low-risk factors has also increased.
Therefore, ways to manage this disease have changed
significantly [3]. Although initial therapy for PC is deter-
mined by risk classification, all treatment options can
have negative impacts on the patient’s quality of life [4].
Over-diagnosing and over-treating have thus become
major concerns for urologists, especially in regards to
low-risk PC [5].
Radical prostatectomy (RP) is a commonly accepted
treatment option; however, the possibility of complications
during surgical process is a considerable risk factor.
Although introduction of robotic surgery has provided
significant improvements in outcomes, the risks for urin-
ary incontinence and sexual dysfunction still exist [6, 7].
For now, active surveillance (AS) is being considered for
select patients with low-risk, organ-confined PC [2]. Sev-
eral standards have also been proposed to assess the utility
of AS [8]. However, in some studies, patients with low-
risk PC, who were eligible for AS, showed adverse patho-
logic features (APFs) after RP [9, 10]. Despite stringent
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selection of only low-risk PC, only a quarter of AS pa-
tients had pathologically insignificant PC [10]. Even in the
low-risk PC group, PC patients with APFs after RP should
be considered for adjuvant radiotherapy [11] and these pa-
tients should avoid under-treatment. There have been sev-
eral reports which propose criteria to predict worse
pathologic outcome; however, predictors for APFs in low-
risk PC group by current criteria are limited. In this study,
we aimed to investigate predictors for APFs following RP
in the low-risk PC group.
Methods
Data were collected after approval from the Institutional
Review Board at Yonsei University College of Medicine
(No. 4–2017-0492). Authors retrospectively reviewed
medical records of 4440 patients who underwent RP
from 1992 to 2014. RP was performed by multiple sur-
geons using open or robot-assisted laparoscopic tech-
niques. After exclusion of patients with incomplete
medical records and those who received neoadjuvant
therapy, patients were classified for preoperative risk
group according to NCCN® guidelines. Low-risk PC was
defined as PC with clinical T1–T2a, Gleason score (GS)
≤ 6, and PSA levels < 10 ng/mL. Grading system was
used according to the 2005 International Society of Uro-
logical Pathology (ISUP) Consensus [12]. TNM stage
was determined according to the American Joint Com-
mittee on Cancer’s 8th edition TNM staging system.
According to our selection criteria, 546 patients with
low-risk PC were included in this study. Data for these
patients included age, body mass index (BMI), type of
operation, preoperative PSA, prostate volume measured
by transrectal ultrasonography (TRUS), number of pros-
tate biopsy cores taken, number of positive cores ob-
served, percentage of positive cores, and pathologic
characteristics of specimens following RP. Maximal per-
centage in each biopsy core was defined as the highest
percentage of tumor present in each individual biopsy
core. All pathologic diagnosis was performed by expert
pathologists. Biopsy specimens obtained from outside of
our hospital were reviewed by our pathologists. The pri-
mary endpoint was occurrence of APFs after RP in low-
risk PC group. APFs were defined as extracapsular ex-
tension (ECE), seminal vesicle invasion (SVI), and posi-
tive surgical margin (PSM) [13]. Tumor volume, which
was defined as the combined volume of all nodules, was
calculated using a grid method [14].
Univariable and multivariable logistic regression ana-
lyses were performed on clinical parameters to investi-
gate predictors for APFs following RP in our low-risk
PC cohort. In addition, clinical predictors for each type
of APF were also analyzed. Receiver operator character-
istics (ROC) curve analysis was performed to determine
optimal cut-off value via area under curve (AUC).
Youden’s Index in ROC curves was used to select an opti-
mal cutoff value of related parameters for predicting APFs.
All statistical analysis was performed out using SPSS Sta-
tistics software version 23.0 (IBM, Armonk, NY, USA).
Results
Baseline characteristics of patients in the study group
are displayed in Table 1. Median age for patients was
64 years (Interquartile range [IQR] 59–69). Median
prostate volume, as measured by TRUS, was 24.1 ml
(IQR 25–42), and median PSA level was 5.6 ng/mL (IQR
4.5–7.0). Median number of biopsy cores taken was 12
Table 1 Baseline characteristics
Variables (n = 546) Median IQR
Age, year 64 59–69
BMI, kg/m2 24.1 22.3–25.7
Year of operation (n/%)
~ 2005 46 8.4
2006~ 2009 365 66.8
2010~ 2014 135 24.7
Type of operation (n/%)
Open 146 26.7
Robotic 400 73.3
Prostate volume measured by TRUS, ml 31.0 25.0–42.0
PSA, ng/ml 5.6 4.5–7.0
Number of biopsy core 12 12–12
Number of positive core 2 1–3
Percentage of positive core, % 16.7 8.3–25.0
Maximal percentage in each biopsy core, % 30.0 10.0–50.0
Prostate volume in specimen, ml 33.0 26–41.1
Tumor volume in specimen, ml 0.8 0.3–1.8
Tumor / Prostate ratio 0.03 0.01–0.06
Extracapsular extension (n/%) 199 36.4
Seminal vesicle invasion (n/%) 8 1.5
Positive surgical margin (n/%) 179 32.8
GS after radical prostatectomy (n/%)
GS 6 (3 + 3) 336 61.5
GS 7 (3 + 4) 143 26.2
GS 7 (4 + 3) 48 8.8
GS 8 (4 + 4) 13 2.4
GS 9 or 10 6 1.1
GS upgrading (n/%) 210 38.5
Perineural invasion (n/%) 175 32.1
Lymphovascular invasion (n/%) 12 2.2
HGPIN (n/%) 308 56.4
BMI=Body mass index; GS = Gleason score; HGPIN=High grade prostatic
intraepithelial neoplasia; PSA = Prostate specific antigen;
TRUS = Transrectal ultrasonography
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(IQR 12–12) with a median number of two positive
cores (IQR 1–3). Median percentage of positive cores
was 16.7% (IQR 8.3–25.0). Additionally, median maximal
percentage in each positive core was 30.0% (IQR 10.0–
50.0). Median tumor volume of specimens following RP
was 0.8 ml (IQR 0.3–1.8). ECE was present in 199 cases
(36.4%), and surgical margins were involved in 179 cases
(32.8%). Invaded seminal vesicles were observed in eight
cases (1.5%). No lymph node metastasis was reported.
GS was upgraded in 210 cases (38.5%). Among them,
upgrading to GS 7 (3 + 4) was most common upgrade
(68.1%). Furthermore, GS above 8 was also reported in
19 cases (3.5%). Perineural invasion was reported in 175
cases (32.1%) and lymphovascular invasion was present
in 12 cases (2.2%). PC with high grade prostatic intrae-
pithelial neoplasia was observed in 308 cases (56.4%).
Univariable and multivariable logistic regression ana-
lyses were performed with each clinical parameter for
APFs and each component of APFs. While performing
univariable and multivariable logistic regression analyses
for PSM and PSA levels, number of positive cores was
included as covariates in multivariable logistic regression
model. A positive association was determined by PSA
levels (hazard ratio [HR] 1.14, 95% confidence interval
[CI] 1.03–1.25) and number of positive cores (HR 1.12,
95% CI 1.01–1.24), as reported in Table 2.
According to the logistic regression analysis which in-
cluded PSA level, number and percentage of positive
cores and maximal percentage in each positive cores as
covariates, ECE/SVI was also significantly associated
with PSA levels (HR 1.21, 95% CI 1.09–1.33) and num-
ber of positive cores (HR 1.38, 95% CI 1.23–1.56), as re-
ported in Table 3. Age, BMI, type of operation, and
prostate volumes measured by TRUS were not associ-
ated with adverse outcomes.
PSA levels showed a significant correlation with presence
of APFs (HR 1.21, 95% CI 1.10–1.33) when analyzed for
integrated APFs by same regression analysis model, and
number of positive cores was also correlated with worse
pathologic outcomes (HR 1.33, 95% CI 1.17–1.50), as re-
ported in Table 4.
ROC curve analysis was used to determine optimal cut-
off value by Youden Index in Fig. 1. Optimal cut-off value
for PSA levels, which can predict APFs, was determined
to be 4.5 ng/mL, with AUC of 0.61 (95% CI 0.56–0.66).
We determined the optimal cutoff value for number of
positive cores above 2, which estimated an AUC of 0.62
(95% CI 0.57–0.66). If we considered both parameters to
predict APFs, it would have shown slightly better out-
comes for predictions in Additional file 1: Figure S1.
(AUC= 0.66).
Discussion
PC has been known as one of the most common cancer
types in newly diagnosed population, and the third-
leading cause of death in males [1]. Proportion of low-
risk PC has increased, and treatment options for PC are
known to differ by risk classification [3]. However,
substantial variation in treatment exists in the manage-
ment of localized PC. Localized PC has been treated by
not only RP, but also by external beam radiation and
AS [15]. Due to concerns of over-diagnosis and over-
treatment, AS is considered especially in cases of
low-risk localized PC [16]. AS has become one of the
treatment options for low-risk PC, under the current
NCCN® guidelines [11].
However, in previous studies, APFs were noted after
RP even in low-risk PC cases [10, 17]. Beauval et al. re-
ported that only 26% of patients had “insignificant” PC after
RP, out of 919 total patients eligible for AS. They reported
that 12.5% of patients had extraprostatic extensions, and
GS was upgraded in 34% of patients [10]. Simon et al. in-
vestigated pathologic outcomes of 1097 PCs in candidates
for AS. Of these patients, 7% to 19% had ECE, and 2% to
Table 2 Univariable and Multivariable analysis of factors associated with PSM
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 1.01 (0.98–1.03) 0.64
BMI 1.02 (0.95–1.09) 0.58
Type of operation
Open 1 (ref)
Robotic 1.35 (0.89–2.04) 0.16
Prostate volume measured by TRUS 1.00 (0.99–1.02) 0.53
PSA 1.15 (1.05–1.27) < 0.01 1.14 (1.03–1.25) 0.01
Number of positive biopsy core 1.14 (1.03–1.26) 0.01 1.12 (1.01–1.24) 0.03
Percentage of positive biopsy core 1.01 (1.00–1.02) 0.05
Maximal percentage in each positive core 1.00 (0.99–1.01) 0.57
BMI=Body mass index; PSA = Prostate specific antigen; PSM = Positive surgical margin; TRUS = Transrectal ultrasonography
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9% had SVI [17]. Having PSM was also associated with
poor prognosis when analyzed for recurrence-free survival
and the need for salvage therapy. Ploussard et al. reported
that five-year recurrence-free survival occurred in 57.5% of
cases with PSM, compared to 84.4% of cases with negative
margins [18]. Therefore, prediction of APFs is important in
low-risk PC patients who are eligible for AS. In our study,
approximately 36% of patients had tumor extension
through prostate capsule, and 32% of patients reported
PSM (Table 1).
Patients with APFs should be considered for adjuvant
radiotherapy after RP [13]. Bolla et al. studied long term
results in a randomized controlled trial for postoperative
irradiation after RP in 1005 high-risk PC patients. They
observed biochemical recurrence (BCR) in 39.4% of pa-
tients who received adjuvant therapy, compared to 61.
8% in the observation group. Patients who underwent
postoperative irradiation showed improvements in
biochemical progression-free survival rates and local
tumor control (EORTC trial 22,911) [19]. Additionally,
Swanson et al. evaluated a cohort of 719 patients for
pathologic findings and risk of failure. They suggested
that patients with any of the following factors were can-
didates for adjuvant therapy: ECE, SVI, or margin in-
volvement [20]. Therefore, physicians should offer
adjuvant therapy to patients with APFs observed at RP
[13]. Patients with APFs should consult with both urolo-
gist and radiation oncologist for more complete treat-
ment information [21].
Based on these findings, many researchers have inves-
tigated predictors for APFs necessitating adjuvant ther-
apy in low-risk PC patients. Although some recent
studies discovered new biomarkers for predicting PC ag-
gressiveness [22, 23], these biomarkers have not been
widely used in clinical practice yet.
Prostate biopsy yields information on not only the
presence of cancer, but also GS, histological subtype,
and additional clinical parameters, including number
and percentage of positive cores. In a previous study,
Gao et al. investigated pathologic outcomes of 62 low-
Table 3 Univariable and Multivariable analysis of factors associated with ECE/SVI
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 1.00 (0.98–1.03) 0.77
BMI 1.03 (0.96–1.10) 0.40
Type of operation
Open 1(ref)
Robotic 1.47 (0.98–2.20) 0.07
Prostate volume measured by TRUS 0.99 (0.98–1.00) 0.21
PSA 1.24 (1.12–1.36) < 0.01 1.21 (1.10–1.33) < 0.01
Number of positive biopsy core 1.40 (1.25–1.58) < 0.01 1.38 (1.23–1.56) < 0.01
Percentage of positive biopsy core 1.04 (1.02–1.05) < 0.01 1.01 (0.98–1.04) 0.48
Maximal percentage in each positive core 1.02 (1.01–1.02) < 0.01 1.01 (1.00–1.02) 0.13
BMI=Body mass index; ECE = Extracapsular extension; PSA = Prostate specific antigen; SVI=Seminal vesicle invasion; TRUS = Transrectal ultrasonography;
Table 4 Univariable and Multivariable analysis of factors associated with APFs
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 1.01 (0.99–1.03) 0.40
BMI 1.05 (0.98–1.12) 0.17
Type of operation
Open 1(ref)
Robotic 1.36 (0.93–2.00) 0.11
Prostate volume measured by TRUS 1.00 (0.99–1.02) 0.44
PSA 1.23 (1.13–1.35) < 0.01 1.21 (1.10–1.33) < 0.01
Number of positive biopsy core 1.35 (1.19–1.52) < 0.01 1.33 (1.17–1.50) < 0.01
Percentage of positive biopsy core 1.03 (1.02–1.05) < 0.01 1.01 (1.98–1.04) 0.43
Maximal percentage in each positive core 1.01 (1.00–1.02) < 0.01 1.01 (1.00–1.01) 0.29
APFs = Adverse pathologic features; BMI=Body mass index; PSA = Prostate specific antigen; TRUS = Transrectal ultrasonography;
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risk PC patients with PSA levels ≤10 ng/mL, biopsy GS ≤
7, and clinical cT1c–T2b. They suggested that number
of positive biopsy cores was associated with PSM [24].
Ogawa et al. investigated predictors for organ confined
PC in 54 patients who underwent RP for T1c PC and re-
ported that PSA levels and number of positive cores
were independent predictors for organ confined tumor
[25]. However, previous studies included a relatively
small number of patients, which could cause limitation
in predicting APFs. Our results support these findings
by demonstrating a significant association between num-
ber of positive cores to PSM and pathologic upstaging
(Tables 2 and 3). Number of positive cores is known to
be associated not only with PSM or upstaging, but also
with GS upgrading following RP. Hong et al. investigated
203 patients with low-risk PC defined by D’Amico classi-
fication and 81 patients were upgraded to GS ≥7 after
RP. They reported preoperative PSA levels and number
of positive cores were independent predictors of GS
score upgrading after RP [26]. However, they included
only upgrading of GS for their results, and not for pre-
dictors of upstaging or PSM.
Our findings are similar to those of previous studies
which showed associations between APFs and number
of positive cores observed. However, the criterion for
classification of low-risk PC has become stricter after
these studies were published. Current criteria include
not only preoperative PSA levels, but also biopsy GS and
clinical T stage [11, 27]. Furthermore, low-risk PC is
stratified as low-risk and very low-risk PC, based on
these clinical variables [2, 11]. Therefore, previous stud-
ies utilized outdated staging criteria, in addition to hav-
ing relatively small sample cohorts and had limited
clinical information to suggest cutoff values for predict-
ing APFs in low-risk PC.
We included patients over a wide range of period from
1992 to 2014. However, most of the patients (91.5%) had
undergone RP within 2006 to 2014. Therefore, we used
the 2005 ISUP grading system for PC. Due to limitations
of pathologic reviews of old specimen slides, we could
not re-review the slides before 2005. ISUP Consensus
was newly introduced in 2014 [28], and further valida-
tions will be followed according to the new grading sys-
tem. Meanwhile, predictive performance of ROC curve
was relatively weak in our study, which may be due to
limitations of having subjects with PSA < 10 ng/ml or
limited number of biopsy cores taken.
Our study had several limitations. First, it was retro-
spective review performed at single institution; therefore,
multi-center, prospective studies are still needed. Sec-
ond, biopsy protocol was not standardized as there were
many patients who did not undergo prostate biopsy at
our institution. Though most patients had 12 core biop-
sies, there were some patients with fewer than 12 core
biopsies. Third, low-risk PC has been re-classified more
specifically, with the very low-risk PC category added in
the latest guidelines [11]. However, in this study, very
low-risk PC showed no significant difference in report-
ing APFs after RP, compared to low-risk PC. Last, pres-
ence of APFs was the primary endpoint of this study.
We did not perform an analysis for long term survival of
these patients. Long term data should be followed to
confirm the lasting impact of APFs on low-risk PC.
Despite these limitations, our study remains inform-
ative for clinicians who treat patients with low-risk PC.
For now, clinical APF predictors that recommended ad-
juvant therapy are lacking, especially in low-risk PC, as
classified by current criteria. This is the largest study to
date to investigate predictors for APFs in low-risk PC, as
defined by current staging criteria, considering how
using both the number of positive cores and PSA levels
better predict APFs than by PSA levels alone. In
addition, this study determined the optimal cut-off value
to predict APFs in preoperative clinical practice. These
parameters could predict APFs in low-risk PC, which is
classified by factors such as low PSA, GS, and T stages,
without additional cost, all of which may serve as essen-
tial information before surgical treatment. These find-
ings offer supplemental information to avoid under-
treatment of patients. Randomized studies are needed to
further confirm our findings. We also anticipate more
precise diagnostic tools to become available through
gene analysis in the near future, to further accurately
diagnose and treat PC.
Conclusions
PSA > 4.5 ng/mL and number of positive cores > 2 in
low-risk PC was associated presence of APFs and these
patients should be considered carefully to provide active
Fig. 1 Receiver operator characteristics (ROC) curve of PSA levels
and number of positive cores for predicting presence of adverse
pathologic features
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surveillance. Physicians should be aware of these param-
eters, which can predict APFs, and should avoid under-
treatment of these patients.
Additional file
Additional file 1: Figure S1. Receiver operator characteristics (ROC)
curve of PSA levels, number of positive cores and multivariable logistic
regression model incorporating PSA levels and number of positive cores
for predicting presence of adverse pathologic features. If we considered
both parameters to predict APFs, it would have shown slightly better
outcomes for predictions (AUC = 0.662). (JPG 31 kb)
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